ArticleJournal of general internal medicine2026
Cannabis Legalization and Opioid Prescribing in Veterans Health Administration Patients: 2013-2022.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundCannabis use for chronic pain is legal in many US states. Cannabis legalization may influence opioid prescribing among patients with chronic pain, although evidence remains mixed.
objectiveThis study examined associations between medical and recreational cannabis law (MCL/RCL) enactment and opioid prescribing among Veterans' Health Administration (VHA) patients with chronic pain overall and by age.
designUsing 2013-2022 VHA electronic health records, we extracted ICD-9/10-CM diagnoses of chronic pain and data on opioid prescriptions. We used staggered-adoption difference-in-difference models to estimate associations between MCL/RCL enactment and opioid prescribing.
participantsVHA patients aged 18 to 75 years with chronic pain diagnoses residing in the US. MAIN MEASURES: The primary exposure was cannabis legalization assessed with state-year variables to indicate MCL and/or RCL enactment. States were categorized yearly as No-MCL/RCL, MCL-only, and MCL/RCL. Primary outcomes were dichotomous variables (yes, no) indicating ≥ 30 days of prescription opioids, long-term opioid therapy (LTOT; ≥ 90 consecutive days of prescription opioids without a gap of > 15 days in supply), high-dose opioids (≥ 50 morphine milligram equivalents), and opioid and benzodiazepine co-prescriptions. KEY
resultsCompared to states without cannabis laws, MCL enactment was associated with reductions in ≥30-day opioid prescribing (-0.79 percentage points; 95% CI, -0.86 to -0.71) and LTOT (-0.34; 95% CI, -0.40 to -0.28), but smaller declines in high-dose opioid (0.09; 95% CI, 0.05 to 0.12) and opioid/benzodiazepine co-prescribing (0.11; 95% CI, 0.07 to 0.14). Following RCL enactment (vs MCL), reductions were observed in ≥30-day opioid prescribing (-0.14; 95% CI, -0.19 to -0.08), high-dose opioid prescribing (-0.33; 95% CI, -0.35 to -0.30), and opioid/benzodiazepine co-prescribing (-0.33; 95% CI, -0.36 to -0.31). Associations varied by age, with reductions generally more consistent among adults aged 65-75 years.
conclusionsFindings suggest that greater legal cannabis access may be associated with modest reductions in opioid prescriptions among patients with chronic pain, potentially reflecting changes in patient and clinician treatment decisions related to pain management.
Indexed as
Identifiers
42806224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.